Jump to content
Advertisement

Advertisement

IBS News

Showing topics posted by Health Reporter and posted in for the last 365 days.

This stream auto-updates     

  1. Yesterday
  2. For IBS Awareness Month, a free trial offer to help improve IBS symptoms BioSpace CHICAGO, April 1, 2020 /PRNewswire/ -- During April, IBS Awareness Month, biotech company Glycom is offering a free trial offer of Holigos® IBS Restore for people suffering from abdominal pain, bloating, constipation or diarrhea caused by irritable bowel syndrome (IBS). Patients with IBS will need to reach out to their healthcare professionals to obtain their free product sample. Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8704051-glycom-free-trial-of-holigos-ibs-restore-for-ibs-awareness-month/ View the full article
  3. We have partnered with @AARDATweets to host "A National Briefing: CDC on COVID-19 and Autoimmune Disease" on Friday, April 3 at 2 p.m. EDT. Listen to @DrPeacockCDC, @DCharabaty and others provide updates for people with autoimmune conditions.Register at http://ow.ly/WSCg30quxno (Feed generated with FetchRSS) View the full article
  4. .@US_FDA has requested withdrawal of all ranitidine products (Rx & OTC) from the US market. As part of the ongoing investigation of NDMA presence in ranitidine, they determined that impurity in some ranitidine products increases over time & when stored at higher than room temps. https://twitter.com/FDA_Drug_Info/status/1245368278651830273 (Feed generated with FetchRSS) View the full article
  5. ACG's President Dr. @MarkPochapin of @nyulangone in #NYC working on behalf of patients and educating a #GIfellow Dr Yan Cui #COVID19 #COVID19GI #Gastroenterology #ACGfamily #GIcommunity #GIfellowship @yycui90 https://twitter.com/MarkPochapin/status/1245179540860801024 (Feed generated with FetchRSS) View the full article
  6. Mild COVID-19 Often Appears With Only Gastro Symptoms: Study HealthDay WEDNESDAY, April 1, 2020 (HealthDay News) -- When most people think of COVID-19, they imagine symptoms such as a dry cough and high fever. But new research out of China shows that a minority of cases appear with gastrointestinal symptoms only. In about one-quarter of patients in the new study, diarrhea and other digestive symptoms were the only symptoms seen in mild COVID-19 cases, and those patients sought medical care later than those with respiratory symptoms. "Failure to recognize these patients early and often may lead to unwitting spread of the disease among outpatients with mild illness, who remain undiagnosed and unaware of their potential to infect others," said a team from Union Hospital and Tongji Medical College in Wuhan, China, the original epicenter of the coronavirus pandemic. View the full article
  7. Stacey Missmer, ScD, on the Association Between Endometriosis and IBS in Adolescents MedPage Today Research has shown that there is an association between endometriosis and the risk of irritable bowel syndrome (IBS) in adults. However, adolescents and young women have been underrepresented in these studies and the extent to which there is an association between endometriosis and IBS in this population is unclear. In Clinical Gastroenterology and Hepatology, Stacey Missmer, ScD, scientific director at the Boston Center for Endometriosis, and Amy DiVasta, MD, MMSc, of the division of adolescent/young adult medicine at Boston Children's Hospital, and colleagues, investigated the association between endometriosis and IBS in adolescents, and whether other factors, such as pain disorders or mood disturbances, influence that association. View the full article
  8. Last week
  9. VIDEO with William Chey, MD @umfoodoc, from @umichmedicine , @AmCollegeGastro trustee, on the impact of #COVID19 on use of #telehealth https://www.healio.com/gastroenterology/practice-management/news/online/%7Bd153982a-4380-4693-90bf-8890e371b1e5%7D/video-impact-of-covid-19-on-use-of-telehealth?utm_medium=social&utm_source=twitter&utm_campaign=sociallinks (Feed generated with FetchRSS) View the full article
  10. Important #AmJGastro #COVID19 science via @TODAYshow @BrennanSpiegel #Gastroenterology "Diarrhea, nausea or vomiting may be first signal of coronavirus in some patients" https://www.today.com/health/diarrhea-nausea-or-vomiting-may-be-first-coronavirus-symptoms-some-t177179 via @TODAYshow (Feed generated with FetchRSS) View the full article
  11. ACG Trustee Dr. Wm Chey @umfoodoc via @HealioGastro on #telehealth #COVID19 #COVID19GI "VIDEO: Impact of COVID-19 on use of telehealth" https://www.healio.com/gastroenterology/practice-management/news/online/%7Bd153982a-4380-4693-90bf-8890e371b1e5%7D/video-impact-of-covid-19-on-use-of-telehealth?utm_medium=social&utm_source=twitter&utm_campaign=sociallinks (Feed generated with FetchRSS) View the full article
  12. News from #AmJGastro on #COVID19GI via @HealioGastro @BrennanSpiegel, "Patients with #COVID19 GI symptoms experience delayed diagnosis, viral clearance" https://www.healio.com/gastroenterology/infection/news/online/%7Bf33cb323-6ed6-43e2-a5aa-e10aeaecb863%7D/patients-with-covid-19-gi-symptoms-experience-delayed-diagnosis-viral-clearance?utm_medium=social&utm_source=twitter&utm_campaign=sociallinks (Feed generated with FetchRSS) View the full article
  13. Digestive Symptoms Present in Mild COVID-19 Disease, Sometimes Without Fever Newswise Newswise — March 31, 2020 -- A new study published in pre-print on March 30, 2020 by The American Journal of Gastroenterology is the first analysis of gastrointestinal symptoms reported by COVID-19 patients with mild disease rather than those with moderate or critical illness and finds a unique sub-group with low severity disease marked by presence of digestive symptoms, most notably diarrhea.The authors from Union Hospital and Tongji Medical College in Wuhan, China report that among some of the patients included in the study, these digestive symptoms, particularly diarrhea, were the presentation of COVID-19, and were only later, or never, present with respiratory symptoms or fever. View the full article
  14. Patients with COVID-19 GI symptoms experience delayed diagnosis, viral clearance Healio Patients who develop new-onset digestive symptoms, like diarrhea, after a possible exposure to COVID-19 should be suspected for the illness, according to research published in The American Journal of Gastroenterology. In the study, Xiaohua Hou, MD, PhD, of the division of gastroenterology at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China, and colleagues wrote that these patients should be suspected for COVID-19 even without common respiratory symptoms, such as cough, shortness of breath, sore throat or fever. “This study is vital because it represents the 80% or more of patients who do not have severe or critical disease,” Brennan M.R. Spiegel, MD, MSHS, FACG,director of health research at Cedars Sinai, said in a press release issued by the American College of Gastroenterology. “This is about the more common scenario of people in the community struggling to figure out if they might have COVID-19 because of new-onset diarrhea, nausea, or vomiting.” View the full article
  15. OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D Business Wire SAN FRANCISCO--(BUSINESS WIRE)--OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, has paused new patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D) in response to the COVID-19 pandemic. Frank J. Steinberg, D.O., Head of Medical Oversight and founding Chief Medical Officer at OrphoMed, notified study sites through the contract research organization PPD® that screening should be temporarily stopped as of the end of business Friday, March 27, 2020. “Our goal is to ensure that patient safety, as well as the safety of PPD® and site personnel, is not jeopardized,” Dr. Steinberg stated. “We hope that current ‘shelter in place’ practices in much of the country will decrease the spread of the coronavirus and will lead to a much improved situation and the resumption of study enrollment. In the meantime, we will work diligently to continue the study as planned for all patients currently enrolled to ensure their safety and the integrity of study data.” View the full article
  16. Unraveling gut-to-brain communication paves way for targeted treatments News-Medical.Net Scientists at Flinders University have, for the first time, identified a specific type of sensory nerve ending in the gut and how these may 'talk' to the spinal cord, communicating pain or discomfort to the brain. This discovery is set to inform the development of new medications to treat problems associated with gut-to-brain communication, paving the way for targeted treatments to mitigate related dysfunction. While our understanding of the gut's neurosensory abilities has grown rapidly in recent years, two of the great mysteries have been where and how the different types of sensory nerve endings in the gut lie, and how they are activated. View the full article
  17. Thanks @PsyLupe for this video!! Great resource for all of us. #TuesdayNightIBS https://twitter.com/PsyLupe/status/1244682540323127298 (Feed generated with FetchRSS) View the full article
  18. RT @SpecialtyDocs: Today is #DoctorsDay ! The stories of #specialtydocs and providers all over the country in response to #Covid19 is nothing short of heroic. THANK YOU!! (Feed generated with FetchRSS) View the full article
  19. RT @WorldIBSDay: Writing to you today during unprecedented #COVID19 epidemic which has taken over our health systems, our thoughts & conversations with many uncertainties, stressing our social & professional lives, our health & finances, & shaking our emotional wellbeing. http://worldibsday.org/friends-of-world-ibs-day/ (Feed generated with FetchRSS) View the full article
  20. Irritable bowel syndrome not associated with increased death risk Medical Dialogues A nationwide study in Sweden shows no increased risk of death among patients with IBS. Irritable bowel syndrome (IBS) is associated with healthcare-seeking behavior and patient anxiety over the possibility of underlying organic disease and shortened lifespan. Researchers have found that there was no increased risk of death among patients with IBS. However, these results should provide reassurance to IBS sufferers and their healthcare providers that lifespan is unlikely to be affected. https://medicaldialogues.in/gastroenterology/news/irritable-bowel-syndrome-not-associated-with-increased-death-risk-64369 View the full article
  21. Related ArticlesGut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: Recent developments and future perspectives. Turk J Med Sci. 2020 Mar 28;: Authors: Dale HF, Lied GA Abstract Increased knowledge regarding the implications of gut microbiota in irritable bowel syndrome (IBS), suggest that a disturbed intestinal microenvironment (dysbiosis) might promote the development and maintenance of IBS symptoms and effects several pathways in the pathology of this multifactorial disease. Accordingly, manipulation of the gut microbiota in order to improve IBS symptoms has the last decade evolved as a novel treatment strategy. Several different approaches have been investigated in order to improve the gut microbiota composition. Dietary modifications including supplementation with fibers, prebiotics and probiotics are shown to improve symptoms and composition of gut microbiota in IBS, however the exact probiotic mixture beneficial for each individual remains to be identified. The use of antibiotics still needs confirmation, although promising results have been reported with use of rifaximin. Fecal microbiota transplantation (FMT) has recently gained a lot of attention, and several placebo-controlled trials investigating FMT pose promising results regarding symptom reduction and gut microbiota manipulation in IBS. However, more data regarding long-term effects is needed before FMT can be integrated as a customised treatment for IBS in the clinical routine. PMID: 32222124 [PubMed - as supplied by publisher] View the full article
  22. Nerve finding unravels gut mysteries Mirage News Scientists at Flinders University have, for the first time, identified a specific type of sensory nerve ending in the gut and how these may ‘talk’ to the spinal cord, communicating pain or discomfort to the brain. This discovery is set to inform the development of new medications to treat problems associated with gut-to-brain communication, paving the way for targeted treatments to mitigate related dysfunction. View the full article
  23. RT @DrvanTilburg: “we are learning that hospitals might be the main Covid-19 carriers, as they are rapidly populated by infected patients, facilitating transmission to uninfected patients” Stay away from hospitals if you can. #COVID19 https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0080?fbclid=IwAR0wa6jzq-t_YYlZlYQtWiVmphT8pjyGBCndLhJGSN34dBaeZJoGP0sfneo (Feed generated with FetchRSS) View the full article
  24. Here are some greet suggestions for #grocery shopping during this #COVID19 #pandemic from GI dietitian, @ea_haller! Thanks, Emily! We’ve been storing things in our garage for a couple days. https://twitter.com/ea_haller/status/1244268581866659842 (Feed generated with FetchRSS) View the full article
  25. Related ArticlesDiscriminant and convergent validity of the GSRS-IBS symptom severity measure for irritable bowel syndrome: A population study. United European Gastroenterol J. 2020 Jan 14;:2050640619900577 Authors: Ljótsson B, Jones M, Talley NJ, Kjellström L, Agréus L, Andreasson A Abstract BACKGROUND: The Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) is a 13-item measure of IBS symptom severity. The scale has been used in several studies, but its psychometric properties have been insufficiently investigated and population-based data are not available. OBJECTIVE: The objective of this article is to establish the factor structure and discriminant and convergent validity of the GSRS-IBS. METHODS: The study was based on a Swedish population sample (the Popcol study), of which 1158 randomly selected participants provided data on the GSRS-IBS. We used confirmatory factor analysis (CFA) and compared total and subscales scores in different groups, including IBS diagnostic status, treatment-seeking behavior, and predominant bowel habits. The GSRS-IBS scores were also correlated with quality of life indexes. RESULTS: The sample included 164 participants with a confirmed Rome III IBS diagnosis and 994 participants without the disease. The CFA confirmed the subscales with one exception, in which the incomplete bowel-emptying item belonged to the constipation subscale rather than the diarrhea subscale. The GSRS-IBS total score and subscales were associated with diagnostic status, treatment-seeking behavior, and quality of life dimensions. The relevant subscales scores also differed between the diarrhea- and constipation-predominant subtypes of IBS. CONCLUSION: The GSRS-IBS total score and subscales have high discriminant and convergent validity. The CFA confirmed the overall validity of the subscales but suggest that a sense of incomplete emptying belongs to the constipation rather than the diarrhea symptom cluster. We conclude that the GSRS-IBS is an excellent measure of IBS symptom severity in the general population. PMID: 32213021 [PubMed - as supplied by publisher] View the full article
  26. Related ArticlesEpidemiology of Functional Abdominal Pain Disorders and Functional Defecation Disorders in Adolescents in Curacao. J Pediatr Gastroenterol Nutr. 2020 Apr;70(4):e71-e76 Authors: Zeevenhooven J, van der Heijden S, Devanarayana NM, Rajindrajith S, Benninga MA Abstract OBJECTIVES: Functional abdominal pain disorders (FAPDs) and functional defecation disorders (FDDs) are common in children and adolescents, but prevalence rates from the Caribbean are lacking. Therefore, our aim was to determine the prevalence of FAPDs and FDDs in adolescents in Curacao and to assess the influence of psychosocial factors on the prevalence of FAPDs and FDDs. METHODS: The prevalence of FAPDs and FDDs in children and adolescents living in Curacao, ages 11 to 18 years, was assessed using the Rome IV Questionnaire on Pediatric Gastrointestinal Disorders (RIV-QPGD). FAPDs and FDDs were diagnosed according to the Rome IV criteria. Sociodemographic characteristics, somatic symptoms, early adverse life events, stressful life events, and physical and emotional abuse were evaluated as associated factors. RESULTS: Out of 946 questionnaires distributed, 783 were included for further analysis. The mean age of adolescents was 14.7 years (±1.6) with 61.7% being girls. A total of 266 adolescents (34%, 95% confidence interval [CI] 30.7-37.5) met Rome IV criteria for at least 1 FAPD or FDD. Twenty-nine adolescents (3.7%) qualified for 2 functional gastrointestinal disorders. Functional constipation (18.6%) and irritable bowel syndrome (12.3%) were the most prevalent disorders. After multivariate logistic regression analyses, dizziness (odds ratio [OR] 1.84, 95% CI 1.28-2.64) was significantly associated with having a FAPD or FDD. CONCLUSIONS: FAPDs and FDDs are common in adolescents in Curacao. Dizziness is associated with the presence of a FAPD or FDD. PMID: 32213782 [PubMed - in process] View the full article
  27. RT @ahmad_abuheija: Great first GI Grand Rounds by @umfoodoc. 👇🏼👇🏼👇🏼 key points from the presentation. Thank you @AmCollegeGastro One good thing that came out of this #COVID19 pandemic. #StayHome #MedEd #GIHomeSchooling (Feed generated with FetchRSS) View the full article
  1. Load more activity
Advertisement



×
×
  • Create New...